BR112013023914A2 - derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio - Google Patents

derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio

Info

Publication number
BR112013023914A2
BR112013023914A2 BR112013023914A BR112013023914A BR112013023914A2 BR 112013023914 A2 BR112013023914 A2 BR 112013023914A2 BR 112013023914 A BR112013023914 A BR 112013023914A BR 112013023914 A BR112013023914 A BR 112013023914A BR 112013023914 A2 BR112013023914 A2 BR 112013023914A2
Authority
BR
Brazil
Prior art keywords
oxazine
receptor modulators
benzo derivatives
calcium sensor
sensor receptor
Prior art date
Application number
BR112013023914A
Other languages
English (en)
Inventor
Chetan Sanjay Pawar
Ganesh Navinchandra Gote
Mahadeo Bhaskar Tryambake
Majid Bashir Sayyed
Manojkumar Ramprasad Shukla
Pachpute Dilip Vipul
Rajender Kumar Kamboj
Sanjeev Anant Kulkarni
Sarde Gangaram Ankush
Venkata P Palle
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112013023914A2 publication Critical patent/BR112013023914A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112013023914A 2011-03-18 2012-03-16 derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio BR112013023914A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
BR112013023914A2 true BR112013023914A2 (pt) 2016-12-13

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023914A BR112013023914A2 (pt) 2011-03-18 2012-03-16 derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio

Country Status (15)

Country Link
US (1) US9464063B2 (pt)
EP (1) EP2686306B1 (pt)
JP (1) JP6033835B2 (pt)
KR (1) KR20140051846A (pt)
CN (1) CN103459377B (pt)
AP (1) AP2013007153A0 (pt)
AU (1) AU2012232706B2 (pt)
BR (1) BR112013023914A2 (pt)
CA (1) CA2829466A1 (pt)
EA (1) EA024893B9 (pt)
IL (1) IL228461A0 (pt)
MX (1) MX2013010670A (pt)
SG (1) SG193331A1 (pt)
WO (2) WO2012127385A1 (pt)
ZA (1) ZA201306837B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112679C2 (uk) * 2012-02-24 2016-10-10 Люпін Лімітед Заміщені хроманові сполуки як модулятори рецептора, чутливого до кальцію
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
IN2015MN00421A (pt) 2012-08-27 2015-09-04 Lupin Ltd
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
PE20160546A1 (es) 2013-10-25 2016-05-26 Novartis Ag Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3551176A4 (en) * 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3568135B1 (en) 2017-01-11 2021-04-07 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
CN114901273A (zh) * 2019-12-27 2022-08-12 鲁平有限公司 Casr调节剂的药物组合物及其方法和用途
EP4090654A1 (en) * 2020-01-17 2022-11-23 Lupin Limited Methods, processes and intermediates for preparing chroman compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
CN101233132A (zh) * 2005-05-09 2008-07-30 海德拉生物科学公司 调节trpv3功能的化合物
CA2608957C (en) * 2005-05-19 2013-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
CN101547922B (zh) 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
CA2669635A1 (en) * 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivative or salt thereof
AU2008328362A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 ＣａＳＲアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Ｅｇｒ装置及びこれを備えたエンジン装置
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Also Published As

Publication number Publication date
EP2686306B1 (en) 2017-01-04
ZA201306837B (en) 2015-05-27
CA2829466A1 (en) 2012-09-27
AU2012232706A1 (en) 2013-09-26
IL228461A0 (en) 2013-12-31
JP2014510097A (ja) 2014-04-24
AP2013007153A0 (en) 2013-09-30
AU2012232706B2 (en) 2016-12-15
US20140018358A1 (en) 2014-01-16
WO2012127385A1 (en) 2012-09-27
US9464063B2 (en) 2016-10-11
NZ616676A (en) 2015-09-25
CN103459377B (zh) 2016-09-07
JP6033835B2 (ja) 2016-11-30
CN103459377A (zh) 2013-12-18
EP2686306A1 (en) 2014-01-22
EA201370205A1 (ru) 2014-01-30
EA024893B1 (ru) 2016-10-31
SG193331A1 (en) 2013-10-30
MX2013010670A (es) 2013-12-06
EA024893B9 (ru) 2017-01-30
WO2012127388A1 (en) 2012-09-27
KR20140051846A (ko) 2014-05-02

Similar Documents

Publication Publication Date Title
BR112013023914A2 (pt) derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio
BR112013002871A2 (pt) derivados de isoxazolina como agentes antiparasitários
BR112013023068A2 (pt) derivados de isoxazolina espirocíclica como agentes antiparasíticos
CU24152B1 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
BR112013015234A2 (pt) derivados fosforosos como moduladores de receptor de quimiocina
BR112012003704A2 (pt) derivados de 3-amino-5-fenil-5,6-di-hidro-2h[1,4]oxazina
BR112012028519A2 (pt) compostos de 2,5,6,7-tetrahidro-[1,4]oxazepin-3-ilamina ou 2,3,6,7-tetrahidro-[1,4]oxazepin-5-ilamina
HK1210472A1 (en) Spirocyclic derivatives as antiparasitic agents
BRPI1013766A2 (pt) "derivados de isoxazol-piridina como moduladores de gaba"
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
BR112012018401A2 (pt) sensor de posição rotativo
CR20130403A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
BRPI0910607A2 (pt) derivados do ciclohexano espirocíclicos substituídos
ZA201306576B (en) Substituted morpholines as modulators for the calcium sensing receptor
EP2887807A4 (en) NOVEL DERIVATIVES OF BENZIMIDAZOLE HEXAHYDROFURO [3,2-B] FURANE
BR112013021602A2 (pt) derivados de heteroarila como moduladores de nachr alfa7.
CU23870B1 (es) Derivados de ciclopropilamida como moduladores h3
CO6890111A2 (es) Derivados de isoxazolina como compuestos insecticidas
BRPI1009200A2 (pt) derivados de benzo tiadiazepinas como moduladores dos receptores ampa e nmda
BRPI1009428A2 (pt) 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
HK1205117A1 (en) Substituted chroman compounds as calcium sensing receptor modulators
BRPI1008963A2 (pt) 2-mercapto-3-aminopiridina substituída como moduladores de kcnq2/3
CO6811856A2 (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
BRPI1016115A8 (pt) derivados de pirrolidina como antogonistas de receptador de nk3.
CO6900142A2 (es) Derivados de etinilo como moduladores del receptor metatrópico de glutamato

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: LUPIN LIMITED (IN)

B25B Requested transfer of rights rejected

Owner name: LUPIN LIMITED (IN)

B25I Requirement for requested change of headquarter

Owner name: LUPIN LIMITED (IN)

Free format text: A FIM DE ATENDER A ALTERACAO DE ENDERECO REQUERIDA ATRAVES DA PETICAO NO 870160061657 DE 21/10/2016, E NECESSARIO APRESENTAR DOCUMENTACAO PARA QUE O INTERESSADO SEJA O TITULAR DO PEDIDO.

B25H Request for change of headquarter rejected

Owner name: LUPIN LIMITED (IN)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 87016061657 DE 21/10/2016,POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2486, DE 28/08/2018.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI